From: gts (gts_2000@yahoo.com)
Date: Sat Feb 15 2003 - 13:09:48 MST
For those of you with open minds and optimistic attitudes, here is yet
*another* research abstract about the benefits of selegiline. (I think I've
posted at least a dozen such abstracts now!)
Rafal, as far as I can tell you are not interested in fairly evaluating
selegiline (deprenyl). You seem entrenched in your close-minded role as
nay-sayer. I'm quite sure there is nothing I could post here short of
absolute proof positive that would persuade you of the immense promise of
this drug for life-extension and cognitive enhancement purposes. Oh well!
I'm not posting these messages here only for your benefit.
Your attitude by the way also argues against the practice of calorie
restriction in humans, despite its numerous successes in prolonging life in
lab animals.
I offer this information here for others not so close-minded as you.
ABSTRACT
Treatment with L-deprenyl [selegiline] prolongs life in elderly dogs
Ruehl WW, Entriken TL, Muggenburg BA,
Bruyette DS, Griffith WC, Hahn FF
Deprenyl Animal Health,
Overland Park, KS 66210 USA.
Life Sci 1997; 61(11):1037-44
Eighty two beagle dogs ranging in age from 2.8 to 16.4 years and in weight
from 6.3 to 15.8 kg were allotted to 41 pairs and administered placebo or 1
mg/kg L-deprenyl orally once daily for 2 years and 10 weeks. When
survivorship for all dogs in the study was analyzed there was no significant
difference between the L-deprenyl and placebo treated groups, most likely
due to the (expected) survival of virtually all young dogs in both groups
for the duration of the study. To assess whether L-deprenyl treatment begun
in later life might enhance canine longevity in a fashion similar to that
documented in rodents we also examined survival in a subset of elderly dogs
who were between the ages of 10 and 15 yrs at the start of tablet
administration and who received tablets for at least 6 months. In this
subset, dogs in the L-deprenyl group survived longer (p < 0.05) than dogs in
the placebo group. Twelve of 15 (80%) dogs in the L-deprenyl group survived
to the conclusion of the study, in contrast to only 7 of 18 (39%) of the
dogs who received placebo (P=0.017). Furthermore, by the time the first
L-deprenyl treated dog died on day 427, 5 placebo treated dogs had already
succumbed, the first on day 295. Specifically with respect to dogs, the
findings reported herein suggest daily oral administration of 1 mg/kg
L-deprenyl prolongs life when begun in relatively healthy dogs 10-15 years
of age and maintained for the duration of the individual's life, but in any
event for no less than six months
This archive was generated by hypermail 2.1.5 : Sat Feb 15 2003 - 13:12:50 MST